Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. XOMA
XOMA logo

XOMA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Xoma Royalty Corp (XOMA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
26.960
1 Day change
-1.17%
52 Week Range
39.920
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Xoma Royalty Corp (XOMA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has a promising royalty portfolio and positive analyst sentiment, the recent financial performance shows significant declines in net income and EPS. The technical indicators are neutral, and there are no strong trading signals or news catalysts to justify immediate action.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 51.123, and moving averages are converging. The stock is trading near its pivot level of 26.029, with support at 24.906 and resistance at 27.152. Overall, no clear bullish or bearish trend is identified.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
7

Positive Catalysts

  • Analysts have raised price targets, with Leerink increasing it to $50 and Lucid Capital initiating coverage with a $76 target. The company's diversified royalty portfolio reduces single-asset risk and has potential for long-term value creation.

Neutral/Negative Catalysts

  • The company's financials for 2025/Q3 show a significant decline in net income (-148.26% YoY) and EPS (-144.03% YoY), despite a 29.93% increase in revenue. Additionally, there is no recent news or significant trading trends from insiders or hedge funds.

Financial Performance

In 2025/Q3, revenue increased by 29.93% YoY to $9,351,000. However, net income dropped by -148.26% YoY to $8,981,000, and EPS fell by -144.03% YoY to 0.7. Gross margin remained stable at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are optimistic, with Leerink raising the price target to $50 and Lucid Capital setting a $76 target. Both firms highlight the company's diversified royalty portfolio and potential for long-term value creation.

Wall Street analysts forecast XOMA stock price to rise
5 Analyst Rating
Wall Street analysts forecast XOMA stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 27.280
sliders
Low
50
Averages
71
High
97
Current: 27.280
sliders
Low
50
Averages
71
High
97
Leerink
Outperform
upgrade
$45 -> $50
AI Analysis
2026-02-24
Reason
Leerink
Price Target
$45 -> $50
AI Analysis
2026-02-24
upgrade
Outperform
Reason
Leerink raised the firm's price target on Xoma to $50 from $45 and keeps an Outperform rating on the shares.
Lucid Capital
NULL -> Buy
initiated
$76
2025-12-09
Reason
Lucid Capital
Price Target
$76
2025-12-09
initiated
NULL -> Buy
Reason
Lucid Capital initiated coverage of Xoma with a Buy rating and $76 price target. The company has assembled a royalty portfolio from six commercial and nine Phase 3- stage small molecule and biological assets, the analyst tells investors in a research note. The firm says Xoma expects to collect over $1B in milestones and royalties over the next 15 years. Lucid believes that by building a diversified portfolio, the company mitigates single-asset risk while retaining exposure to substantial long-term value creation.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for XOMA
Unlock Now

People Also Watch